Literature DB >> 2239495

The clinical benefit of NADH as stimulator of endogenous L-dopa biosynthesis in parkinsonian patients.

W Birkmayer1, J G Birkmayer, K Vrecko, B Paletta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2239495

Source DB:  PubMed          Journal:  Adv Neurol        ISSN： 0091-3952


× No keyword cloud information.
  4 in total

1.  Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis.

Authors:  W Kuhn; T Müller; R Winkel; S Danielczik; A Gerstner; R Häcker; C Mattern; H Przuntek
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Neuronal death induced by misfolded prion protein is due to NAD+ depletion and can be relieved in vitro and in vivo by NAD+ replenishment.

Authors:  Minghai Zhou; Gregory Ottenberg; Gian Franco Sferrazza; Christopher Hubbs; Mohammad Fallahi; Gavin Rumbaugh; Alicia F Brantley; Corinne I Lasmézas
Journal:  Brain       Date:  2015-02-11       Impact factor: 13.501

Review 3.  PGC-1α, Sirtuins and PARPs in Huntington's Disease and Other Neurodegenerative Conditions: NAD+ to Rule Them All.

Authors:  Alejandro Lloret; M Flint Beal
Journal:  Neurochem Res       Date:  2019-05-07       Impact factor: 3.996

Review 4.  Is NADH effective in the treatment of Parkinson's disease?

Authors:  R H Swerdlow
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 3.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.